<DOC>
	<DOCNO>NCT02617134</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CAR-T cell immunotherapy patient MUC1 positive relapse refractory solid tumor .</brief_summary>
	<brief_title>CAR-T Cell Immunotherapy MUC1 Positive Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Male female subject MUC1+ malignancy patient available curative treatment option limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol : Eligible disease : MUC1+ malignant glioma brain , colorectal carcinoma gastric carcinoma . 1a . Malignant Glioma Brain Failure previous standard care initial treatment glioblastoma multiforme ; documentation magnetic resonance imaging ( MRI ) interval increase nodular gadolinium enhancement consistent recurrent malignant glioma suitable therapeutic reresection ; previous pathological diagnosis World Health Organization ( WHO ) Grade IV glioma ; 1b . Colorectal Carcinoma Patients must histologically prove adenocarcinoma primary colon rectum clinical pathologic evidence distant metastasis ; 1c . Gastric Carcinoma Histologically confirm adenocarcinoma stomach , gastroesophageal junction esophagus ; metastatic disease locally advanced disease amenable curative surgery . Patients 18 year age old , must life expectancy &gt; 12 week . MUC1 express malignancy tissue immunohistochemical ( IHC ) . Eastern cooperative oncology group ( ECOG ) performance status 02 karnofsky performance status ( KPS ) score high 60 . Adequate venous access apheresis venous sampling , contraindication leukapheresis . Females childbearing potential must negative pregnancy test subject must agree use effective method contraception two week last infusion CAR T cell . Adequate bone marrow , liver renal function assess follow laboratory requirement : White blood cell count ( WBC ) ≥ 2500c/ml , Platelets ≥ 50×10^9/L , Hb ≥ 9.0g/dL , lymphocyte ( LY ) ≥ 0.7×10^9/L , LY % ≥ 15 % , Alb ≥ 2.8g/dL , serum lipase amylase &lt; 1.5×upper limit normal , serum creatinine ≤ 2.5mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5×upper limit normal , serum total bilirubin ≤ 2.0mg/dL . These test must conduct within 7 day prior registration . Ability give inform consent . The transduction efficiency T cell less 30 % amplification T cell via artificial antigen present cell ( aAPC ) stimulation le 5 time . Pregnant nursing woman may participate . Known HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Serious illness medical condition would permit patient manage accord protocol , include active uncontrolled infection , major cardiovascular , coagulation disorder , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive/restrictive pulmonary disease , psychiatric emotional disorder . History severe immediate hypersensitivity agent include cyclophosphamide , fludarabine , aldesleukin . Concurrent use systemic steroid . Recent current use inhale steroid exclusionary . Previously treatment gene therapy product . The existence unstable active ulcer gastrointestinal bleeding . Patients portal vein vascular invasion extrahepatic , exclude study . Patients history organ transplantation wait organ transplantation . Patients need anticoagulant therapy ( warfarin heparin ) . Patients need longterm antiplatelet therapy ( aspirin dose &gt; 300mg/d ; clopidogrel dose &gt; 75mg/d ) . Patients treat radiotherapy within 4 week prior first apheresis . Patients use fludarabine cladribine chemotherapy within two year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>